Evidence map›Paper›PMID 40851054›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Radioligand treatment with [

Marcel Schwinger, Charis Kalogirou, Vincent Scheper, Maximiliane Däuwel, Simon Weber, Anna Katharina Seitz, Hubert Kübler, Andreas K Buck, Rudolf A Werner, Philipp E Hartrampf

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marcel SchwingerDepartment of Urology and Paediatric Urology, University Hospital Wuerzburg, Wuerzburg, Germany. schwinger_m@ukw.de.ORCID 0009-0002-3267-6323
Charis KalogirouDepartment of Urology and Paediatric Urology, University Hospital Wuerzburg, Wuerzburg, Germany.
Vincent ScheperDepartment of Urology and Paediatric Urology, University Hospital Wuerzburg, Wuerzburg, Germany.
Maximiliane DäuwelDepartment of Urology and Paediatric Urology, University Hospital Wuerzburg, Wuerzburg, Germany.
Simon WeberDepartment of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.
Anna Katharina SeitzDepartment of Urology and Paediatric Urology, University Hospital Wuerzburg, Wuerzburg, Germany.
Hubert KüblerDepartment of Urology and Paediatric Urology, University Hospital Wuerzburg, Wuerzburg, Germany.
Andreas K BuckDepartment of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany.
Philipp E HartrampfDepartment of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to evaluate the safety and efficacy to explore predictors of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC) patients aged ≥ 75 and explored baseline predictors of overall survival (OS). MATERIALS AND

methods56 men (median age 78, range 75-95) were treated with RLT. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Baseline Gleason score, blood parameters (PSA, LDH), and sites of metastases (bone, lymph nodes, liver, lung) were recorded. Quantitative PET parameters such as SUVmean (mean standardized uptake value), SUVpeak (peak standardized uptake value), SUVmax (maximum standardized uptake value), PSMA-TV (PSMApositive tumor volume), TL-PSMA (total lesion PSMA) were measured. PET response was assessed by RECIP 1.0 (response evaluation criteria in PSMA imaging); biochemical response by PCWG3 (prostate cancer working group 3). Associations with OS were analyzed via uni- and multivariable Cox regression and Kaplan-Meier curves.

resultsNo CTCAE grade III-V toxicities occurred. Grade I/II hematologic events included anemia (23.2%), leukocytopenia (18.6%) and thrombocytopenia (9.3%); eGFR declined by 2.5% (grade I/II in 18.6%). Median OS was 11 months; 60.7% of patients died. 74.4% of patients (32/43) showed PSA declines (median - 58%; 14/43 ≥ 50%). Higher baseline PSA (HR 1.001 per ng/mL; P < 0.10) and LDH (HR 1.008 per U/L; P < 0.01) were associated with shorter OS. Patients with progressive disease by both RECIP and PCWG3 had shorter OS than others (11 vs. 22 months; HR 3.3; P < 0.01). Any PSA response predicted longer OS (21 vs. 7 months; HR 0.3; P < 0.01). Presence of liver metastases portended poorer survival (8 vs. 21 months; HR 6.7; P < 0.001).

conclusion[¹⁷⁷Lu]Lu-PSMA I&T RLT is well tolerated in patients ≥ 75 years. Lower baseline PSA and LDH but not PSMA-TV predict longer OS. Early PSA response strongly correlates with improved survival. Combined use of RECIP and PCWG3 criteria optimizes response assessment.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IILutetiumProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsSafetyAgedAged, 80 and overHumansMalePrognosisProstate-Specific AntigenRadioisotopesTreatment OutcomeAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177PluvictoProstate-Specific AntigenRadioisotopesRadiopharmaceuticals[¹⁷⁷Lu]Lu-PSMA I&TBiochemical and imaging responseElderly patients (≥ 75 years)Overall survival predictorsProstate cancerPSMA-targeted radioligand therapy

Identifiers

PMID40851054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.